Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Polycythemia vera (PV) is a Philadelphia-negative chronic myeloproliferative neoplasm.
• PV is distinguished by erythrocytosis, differing from essential thrombocytosis and primary myelofibrosis.
• While longevity is typical, PV patients face risks of vascular morbidity, disease transformation, and significant symptom burden.

Purpose of the Study:

• To review the contributing factors to the symptomatic burden in Polycythemia vera.
• To examine the multifactorial causes of thrombotic events in PV patients.
• To analyze the progression of PV to myelofibrosis (post-PV MF) and acute myeloid leukemia.

Main Methods:

• Literature review of factors contributing to PV symptoms.
• Analysis of established and hypothesized contributors to thrombosis in PV.
• Examination of risk factors for disease transformation in PV.

Main Results:

• Symptom burden in PV is linked to cytokine release, microvascular issues, and can indicate disease evolution.
• Thrombosis in PV is multifactorial, potentially involving gender, inflammatory stress, microparticles, and Neutrophil Extracellular Trap Formations.
• Risk factors for transformation to post-PV MF and acute myeloid leukemia include age, leukocytosis, treatments, and non-driver mutations.

Conclusions:

• Understanding the diverse contributors to PV symptoms, thrombosis, and transformation is crucial for patient management.
• Further research into microparticles and NETs may offer new therapeutic targets for thrombosis prevention in PV.
• Identifying and managing risk factors is key to improving outcomes and preventing disease progression in Polycythemia vera.